Johnson & Johnson (NYSE:JNJ) Shares Sold by Winslow Asset Management Inc.

Winslow Asset Management Inc. trimmed its position in Johnson & Johnson (NYSE:JNJFree Report) by 33.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 31,372 shares of the company’s stock after selling 15,944 shares during the quarter. Winslow Asset Management Inc.’s holdings in Johnson & Johnson were worth $4,886,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of JNJ. Rather & Kittrell Inc. grew its stake in Johnson & Johnson by 2.0% in the second quarter. Rather & Kittrell Inc. now owns 2,909 shares of the company’s stock worth $481,000 after purchasing an additional 58 shares in the last quarter. Capital Square LLC grew its stake in Johnson & Johnson by 1.4% in the second quarter. Capital Square LLC now owns 4,245 shares of the company’s stock worth $703,000 after purchasing an additional 58 shares in the last quarter. Wagner Wealth Management LLC grew its stake in Johnson & Johnson by 1.3% in the second quarter. Wagner Wealth Management LLC now owns 4,543 shares of the company’s stock worth $752,000 after purchasing an additional 59 shares in the last quarter. Chesapeake Wealth Management grew its stake in Johnson & Johnson by 0.7% in the second quarter. Chesapeake Wealth Management now owns 9,196 shares of the company’s stock worth $1,522,000 after purchasing an additional 60 shares in the last quarter. Finally, RPG Investment Advisory LLC grew its stake in Johnson & Johnson by 1.2% in the second quarter. RPG Investment Advisory LLC now owns 4,876 shares of the company’s stock worth $807,000 after purchasing an additional 60 shares in the last quarter. 68.40% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Down 0.1 %

Shares of JNJ opened at $157.98 on Thursday. Johnson & Johnson has a 52 week low of $144.95 and a 52 week high of $175.97. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21. The firm has a market capitalization of $380.30 billion, a P/E ratio of 11.44, a P/E/G ratio of 2.62 and a beta of 0.53. The company has a 50-day simple moving average of $158.20 and a 200-day simple moving average of $159.04.

Johnson & Johnson (NYSE:JNJGet Free Report) last issued its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $2.28 by $0.01. The firm had revenue of $21.40 billion for the quarter, compared to analysts’ expectations of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. The company’s quarterly revenue was down 9.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.35 earnings per share. On average, equities research analysts expect that Johnson & Johnson will post 10.66 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th will be paid a dividend of $1.19 per share. The ex-dividend date of this dividend is Friday, February 16th. This represents a $4.76 annualized dividend and a yield of 3.01%. Johnson & Johnson’s dividend payout ratio is 34.47%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on JNJ. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Raymond James upped their price target on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. TheStreet cut shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, November 17th. Wells Fargo & Company cut shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $170.00 to $163.00 in a research report on Wednesday, December 13th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Tuesday. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $176.14.

Get Our Latest Analysis on JNJ

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.